Protara Therapeutics (TARA) Cash & Equivalents (2013 - 2026)

Protara Therapeutics (TARA) has reported Cash & Equivalents for 14 consecutive years, with $14.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Equivalents fell 83.89% year-over-year to $14.7 million; the TTM figure through Mar 2026 stood at $14.7 million (down 83.89% YoY), while the FY2025 annual figure was $49.7 million, down 69.5% from the prior year.
• Cash & Equivalents eased to $14.7 million in Q1 2026 per TARA's latest filing, from $49.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $162.8 million in Q4 2024 and bottomed at $12.6 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $52.1 million across 5 years, with a median of $39.6 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Equivalents soared 311.25% — and 2026, when it slumped 83.89%.
• Protara Therapeutics' Cash & Equivalents stood at $94.7 million in 2022, then plunged by 58.19% to $39.6 million in 2023, then jumped by 311.25% to $162.8 million in 2024, then plunged by 69.5% to $49.7 million in 2025, then sank by 70.32% to $14.7 million in 2026.
• Business Quant data shows TARA's Cash & Equivalents at $14.7 million in Q1 2026, $49.7 million in Q4 2025, and $12.6 million in Q3 2025.